Isoflurane Versus Propofol for Removal of LMA in Children
Model scores of the 29,894 trials active now.
Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Completed on 2013-11-30, after 2012-04-30 start.
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-11-30. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Accepts healthy volunteers: Yes (lowers risk) · Who can join
-
Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
-
Wording of the registration (title, summary, criteria) (lowers risk) · Wording
Phrases that raised it: historystudydisordersprocedurescriteria
Phrases that lowered it: patientscombinationiiupperasthma -
Primary purpose: prevention (lowers risk) · Design
-
Responsible party: principal investigator (lowers risk) · Design
-
Minimum age: 2 (lowers risk) · Who can join
-
Design: single group (raises risk) · Design
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Maximum age: 10 (raises risk) · Who can join
-
Blinding: none (raises risk) · Design
-
Phase: 2/3 (raises risk) · Design
-
Drug's FAERS reports marked serious: 93.6% (raises risk) · Drug's FDA history
-
Trials the sponsor started in the prior 2 years: 10 (lowers risk) · Sponsor's track record
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2/3 (typical: 2)
- Number of arms
- 2
- Allocation
- randomized
- Design
- single group (typical: parallel)
- Primary purpose
- prevention (typical: treatment)
- Blinding
- none
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 0
- Keywords listed
- 5 (typical: 1)
Who can join
- Minimum age
- 2 (typical: 18)
- Maximum age
- 10 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- Yes (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 35 (typical: 32)
- Sponsor's past termination rate
- 0% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 10 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 2 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 8067 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 1659 (typical: 412.5)
- Drug's FAERS reports marked serious
- 93.6% (typical: 85.6%)
- Drug's FAERS reports with a death
- 17.3% (typical: 15.9%)
Disease area and drugs
- Disease areas
- none of the 14 tracked areas
- Drugs matched to FDA substances
- isoflurane, propofol
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia NCT02322502 · started 2015 · scored riskier than 12% of active trials completed
- Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine NCT01505933 · started 2012 · scored riskier than 41% of active trials terminated
- Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation. NCT06327399 · started 2024 · scored riskier than 8% of active trials completed
- Role of Airway Topicalization in Awake Fiberoptic Intubation NCT06720220 · started 2023 · scored riskier than 6% of active trials completed
- Laryngeal Reflex Study Under Propofol Anesthesia: Effect of Intravenous Lidocaine NCT01222169 · started 2010 · scored riskier than 15% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.